Cetuximab News and Research

RSS
Cetuximab is an investigational IgG1 monoclonal antibody designed to target and block the Epidermal Growth Factor Receptor (EGFR), which is expressed on the surface of certain cancer cells in multiple tumor types. Cetuximab is designed to bind to EGFR and prevent natural ligands called growth factors from binding to the receptor and inducing phosphorylation, i.e., activation of signaling to the tumor. The most common drug-related adverse events reported in clinical trials of cetuximab have been an acne-like rash and asthenia. Severe allergic reactions may occur in a small percentage of patients.
Identifying colorectal cancer subtypes in patients could help provide better care

Identifying colorectal cancer subtypes in patients could help provide better care

Identifying subtype of colorectal cancer may help oncologists determine most effective treatment

Identifying subtype of colorectal cancer may help oncologists determine most effective treatment

New analysis reveals precision oncology insights for colorectal cancer

New analysis reveals precision oncology insights for colorectal cancer

Monoclonal antibody pembrolizumab prolongs survival in patients with squamous cell carcinoma

Monoclonal antibody pembrolizumab prolongs survival in patients with squamous cell carcinoma

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Toxic effects of drugs in the lungs 'more widespread than thought'

Toxic effects of drugs in the lungs 'more widespread than thought'

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

New model could predict personalized waiting time for progression in colorectal cancer

New model could predict personalized waiting time for progression in colorectal cancer

'Plastic antibodies' effectively target and eliminate tumor cells

'Plastic antibodies' effectively target and eliminate tumor cells

Clinical study suggests new treatment direction for head and neck cancer in heavy smokers

Clinical study suggests new treatment direction for head and neck cancer in heavy smokers

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Researchers develop new methods for studying evolution of cancer treatment resistance

Researchers develop new methods for studying evolution of cancer treatment resistance

Colorado researchers suggest new combination therapy for advanced head and neck cancer

Colorado researchers suggest new combination therapy for advanced head and neck cancer

Researchers explore targeted second-line treatment for colorectal cancer

Researchers explore targeted second-line treatment for colorectal cancer

Highly sensitive ELISA method for analysis of CET in plasma samples

Highly sensitive ELISA method for analysis of CET in plasma samples

Inexplicable cases of anaphylaxis caused by uncommon red meat allergy, study finds

Inexplicable cases of anaphylaxis caused by uncommon red meat allergy, study finds

Scientists discover new non-genetic cause of resistance to anti-cancer therapies

Scientists discover new non-genetic cause of resistance to anti-cancer therapies

Immunotherapy found to be smarter, kinder treatment for people with head and neck cancer

Immunotherapy found to be smarter, kinder treatment for people with head and neck cancer

ASTRO issues new clinical guideline for management of oropharyngeal cancer with radiation therapy

ASTRO issues new clinical guideline for management of oropharyngeal cancer with radiation therapy

Scientists identify new biomarkers that could guide bowel cancer treatment

Scientists identify new biomarkers that could guide bowel cancer treatment